Sovleplenib

Sovleplenib is an investigational new drug that is being evaluated by Hutchison MediPharma^[1] for the treatment of immune thrombocytopenia (ITP)^[2] and warm antibody autoimmune hemolytic anemia (WAIHA).^[3] It has also been shown preclinically to have activity against B-cell lymphoma.^[4] Sovleplenib is a tyrosine-protein kinase SYK inhibitor.^[4]

Other namesHMPL-523

Legal status

• investigational

CAS Number

• 1415792-84-5

PubChem CID

• 71113742

Quick facts Clinical data, Other names ...

Sovleplenib

Clinical data
Other names	HMPL-523
Legal status
Legal status	investigational
Identifiers
IUPAC name 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-N-[[(2S)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine
CAS Number	1415792-84-5
PubChem CID	71113742
IUPHAR/BPS	11886
DrugBank	DB17557
ChemSpider	115010433
UNII	9CL6353KHO
KEGG	D12953
ChEBI	CHEBI:758620
ChEMBL	ChEMBL5641911
Chemical and physical data
Formula	C24H30N6O3S
Molar mass	482.60 g·mol−1
3D model (JSmol)	Interactive image
SMILES CS(=O)(=O)N1CCC(CC1)C2=CC=C(C=C2)C3=CC4=NC=CN=C4C(=N3)NC[C@@H]5CNCCO5
InChI InChI=InChI=1S/C24H30N6O3S/c1-34(31,32)30-11-6-18(7-12-30)17-2-4-19(5-3-17)21-14-22-23(27-9-8-26-22)24(29-21)28-16-20-15-25-10-13-33-20/h2-5,8-9,14,18,20,25H,6-7,10-13,15-16H2,1H3,(H,28,29)/t20-/m0/s1 Key:NJIAKNWTIVDSDA-FQEVSTJZSA-N

Close